153 related articles for article (PubMed ID: 18045061)
21. Structural basis for the inhibitor recognition of human Lyn kinase domain.
Miyano N; Kinoshita T; Nakai R; Kirii Y; Yokota K; Tada T
Bioorg Med Chem Lett; 2009 Dec; 19(23):6557-60. PubMed ID: 19857964
[TBL] [Abstract][Full Text] [Related]
22. Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
El-Moghazy SM; George RF; Osman EEA; Elbatrawy AA; Kissova M; Colombo A; Crespan E; Maga G
Eur J Med Chem; 2016 Nov; 123():1-13. PubMed ID: 27474918
[TBL] [Abstract][Full Text] [Related]
23. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
24. Recent progress of SRC family kinase inhibitors as anticancer agents.
Cao X; You QD; Li ZY; Wang XJ; Lu XY; Liu XR; Xu D; Liu B
Mini Rev Med Chem; 2008 Sep; 8(10):1053-63. PubMed ID: 18782057
[TBL] [Abstract][Full Text] [Related]
25. SRC inhibitors as potential therapeutic agents for human cancers.
Trevino JG; Summy JM; Gallick GE
Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
[TBL] [Abstract][Full Text] [Related]
26. Inhibiting Src family tyrosine kinase activity blocks glutamate signalling to ERK1/2 and Akt/PKB but not JNK in cultured striatal neurones.
Crossthwaite AJ; Valli H; Williams RJ
J Neurochem; 2004 Mar; 88(5):1127-39. PubMed ID: 15009668
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of 1,4-disubstituted 1,2,3-triazole Derivatives Using Click Chemistry and their Src Kinase Activities.
Lebeau A; Abrioux C; Bénimèlis D; Benfodda Z; Meffre P
Med Chem; 2016; 13(1):40-48. PubMed ID: 27041552
[TBL] [Abstract][Full Text] [Related]
28. A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability.
Temps C; Lietha D; Webb ER; Li XF; Dawson JC; Muir M; Macleod KG; Valero T; Munro AF; Contreras-Montoya R; Luque-Ortega JR; Fraser C; Beetham H; Schoenherr C; Lopalco M; Arends MJ; Frame MC; Qian BZ; Brunton VG; Carragher NO; Unciti-Broceta A
Cancer Res; 2021 Nov; 81(21):5438-5450. PubMed ID: 34417202
[TBL] [Abstract][Full Text] [Related]
29. Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms.
Crespan E; Radi M; Zanoli S; Schenone S; Botta M; Maga G
Bioorg Med Chem; 2010 Jun; 18(11):3999-4008. PubMed ID: 20451394
[TBL] [Abstract][Full Text] [Related]
30. Src: regulation, role in human carcinogenesis and pharmacological inhibitors.
Tsygankov AY; Shore SK
Curr Pharm Des; 2004; 10(15):1745-56. PubMed ID: 15180537
[TBL] [Abstract][Full Text] [Related]
31. Last findings on dual inhibitors of abl and SRC tyrosine-kinases.
Schenone S; Manetti F; Botta M
Mini Rev Med Chem; 2007 Feb; 7(2):191-201. PubMed ID: 17305593
[TBL] [Abstract][Full Text] [Related]
32. Pyrazolo pyrimidine-type inhibitors of SRC family tyrosine kinases promote ovarian steroid-induced differentiation of human endometrial stromal cells in vitro.
Maruyama T; Yamamoto Y; Shimizu A; Masuda H; Sakai N; Sakurai R; Asada H; Yoshimura Y
Biol Reprod; 2004 Jan; 70(1):214-21. PubMed ID: 14522827
[TBL] [Abstract][Full Text] [Related]
33. Fyn tyrosine kinase is a critical regulator of disabled-1 during brain development.
Arnaud L; Ballif BA; Förster E; Cooper JA
Curr Biol; 2003 Jan; 13(1):9-17. PubMed ID: 12526739
[TBL] [Abstract][Full Text] [Related]
34. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
35. Src signaling in cancer invasion.
Guarino M
J Cell Physiol; 2010 Apr; 223(1):14-26. PubMed ID: 20049846
[TBL] [Abstract][Full Text] [Related]
36. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
[TBL] [Abstract][Full Text] [Related]
37. SRC inhibitors and angiogenesis.
Schenone S; Manetti F; Botta M
Curr Pharm Des; 2007; 13(21):2118-28. PubMed ID: 17627544
[TBL] [Abstract][Full Text] [Related]
38. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
Garcia R; Bowman TL; Niu G; Yu H; Minton S; Muro-Cacho CA; Cox CE; Falcone R; Fairclough R; Parsons S; Laudano A; Gazit A; Levitzki A; Kraker A; Jove R
Oncogene; 2001 May; 20(20):2499-513. PubMed ID: 11420660
[TBL] [Abstract][Full Text] [Related]
39. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities.
Liu Y; Witucki LA; Shah K; Bishop AC; Shokat KM
Biochemistry; 2000 Nov; 39(47):14400-8. PubMed ID: 11087392
[TBL] [Abstract][Full Text] [Related]
40. An update on dual Src/Abl inhibitors.
Musumeci F; Schenone S; Brullo C; Botta M
Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
